Compare ASMB & HYLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASMB | HYLN |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Construction/Ag Equipment/Trucks |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 440.0M | 348.4M |
| IPO Year | 2010 | 2019 |
| Metric | ASMB | HYLN |
|---|---|---|
| Price | $28.30 | $2.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | ★ $43.40 | $5.00 |
| AVG Volume (30 Days) | 92.6K | ★ 926.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $3,475,000.00 |
| Revenue This Year | $33.33 | $32.29 |
| Revenue Next Year | N/A | $174.03 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 130.28 |
| 52 Week Low | $7.76 | $1.11 |
| 52 Week High | $39.71 | $2.56 |
| Indicator | ASMB | HYLN |
|---|---|---|
| Relative Strength Index (RSI) | 48.18 | 52.20 |
| Support Level | $26.50 | $1.85 |
| Resistance Level | $30.66 | $2.26 |
| Average True Range (ATR) | 1.46 | 0.13 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 36.74 | 61.25 |
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
Hyliion Holdings Corp provides solutions that enable clean, flexible, and affordable electricity production. The Company focuses on delivering distributed power generators that can operate on various fuel sources to future-proof against an ever-changing energy economy. It is initially targeting the commercial and waste management industries with a locally deployable generator that can offer prime power as well as energy arbitrage opportunities. In addition to stationary power solutions, it focuses on mobile applications, including vehicles and marine technologies.